|
KMID : 1141720210090020090
|
|
폐쇄성폐질환
2021 Volume.9 No. 2 p.90 ~ p.93
|
|
|
Current Updates in the Triple Therapy for Asthma
|
|
Lee Chang-Hoon
|
|
|
Abstract
|
|
|
|
Large-scale randomized controlled trials have shown that triple inhaled therapy including inhaled corticosteroids (ICSs), long-acting beta2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) is more efficacious than ICS/LABA therapy. These studies showed triple therapy can be surely good treatment option for patients with uncontrolled asthma although the differences in treatment effect size were modest. The present paper also attempted to answer the following questions: When adding LAMA is most effective? When high dose ICS should be used? Will triple therapy show a comparable or better efficacy to biologics for those with type 2 phenotype asthma?
|
|
|
KEYWORD
|
|
|
Asthma, Long-acting muscarinic antagonist, Triple therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|